The Women’s Alzheimer’s Movement recognizes that women are at the epicenter of the global Alzheimer’s epidemic and believe that cutting edge research on women’s brains is necessary to change the course of the disease. We raise money for critical women-based research and instigate the creation of women-based initiatives at leading scientific institutions, universities, foundations and organizations. We partner with leading researchers and non-profit organizations that share our vision and hope to create women’s Alzheimer’s research funds that finance high potential, gender-based scientific investigations. We are aggressively seeking answers to the question: Why are women disproportionately affected by Alzheimer’s and related dementias? Answering that question requires a sharp focus on what is particular to women’s biology, genetics, and lifestyle.
While we recognize there is some gender specific research underway in labs around the country, we also know that there has not been a sufficient emphasis placed on determining the relationship between a women’s biological and genetic make-up and the fact that women are being diagnosed with Alzheimer’s, dementias and other neurological disorders at staggering rates.
The myriad of gender specific factors like hormone levels, genetic composition, age-related variables, and lifestyle practices, provide a broad basis for the research that is essential to finding the answer that we hope will lead to breakthrough discoveries with far-reaching impact on the future of Alzheimer’s disease for women, men, and families everywhere.
The Women’s Alzheimer’s Movement is proud to award research grants to the following:
The Alzheimer’s Association’s mission is to eliminate Alzheimer’s disease through the advancement of research; to provide and enhance care and support for all affected; and to reduce the risk of dementia through the promotion of brain health.
The Alzheimer’s Association works on a global, national and local level to enhance care and support for all those affected by Alzheimer’s and other dementias. As the largest nonprofit funder of Alzheimer’s research, the Association is committed to accelerating the global progress of new treatments, preventions and ultimately, a cure.
The Association reaches millions of people affected by Alzheimer’s across the globe through our national office and chapters in communities nationwide. They are the world’s leading voluntary health organization in Alzheimer’s care, support and research.
Cure Alzheimer’s Fund
Cure Alzheimer’s Fund is a non-profit organization dedicated to funding research with the highest probability of preventing, slowing or reversing Alzheimer’s disease through venture-based philanthropy.
Since its founding, Cure Alzheimer’s Fund has contributed more than $36,000,000 to research, and its funded initiatives have been responsible for several key breakthroughs—including a potential treatment recently selected by the National Institutes of Health (NIH) for its elite “Blueprint” drug discovery program, and the ground-breaking “Alzheimer’s in a Dish” study, which promises to greatly accelerate drug testing and was reported by the New York Times as a “giant step forward”.
Cure Alzheimer’s Fund supports some of the best scientific minds in the field of Alzheimer’s research, and it does so without any financial gain for its founders or donors. Fully 100 percent of funds raised by Cure Alzheimer’s Fund go directly to research—the Board of Directors covers all overhead expenses.
Lou Ruvo Center at The Cleveland Clinic
Cleveland Clinic Lou Ruvo Center for Brain Health provides diagnosis and ongoing treatment for patients with cognitive disorders and support services for family members who care for them. Across our four locations: Cleveland and Lakewood, Ohio; Las Vegas, Nevada and Weston, Florida, they advocate a patient-focused, multidisciplinary approach for the diagnosis and treatment of cognitive disorders, encouraging collaboration across all care providers and by providing a continuum of care, integrating research and education at every level.
Their treatment programs are designed to provide excellent care and to respect the dignity of patients and their families. Their collaborative research partnerships help to advance Cleveland Clinic’s groundbreaking clinical trials and offer hope for improving brain health.
An individualized treatment plan is developed for each patient who is treated at the Lou Ruvo Center for Brain Health. The plan is tailored to each patient and may include recommendations for medications, physical exercise, diet, cognitive rehabilitation, psychiatric treatment (when needed), participation in clinical trials and family support.
Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital
The Ann Romney Center for Neurologic Diseases is transforming the future of medicine through novel forms of collaboration and patient-centered research. This collaboration—within and outside our walls—is accelerating the search for treatments, prevention, and cures for five of the world’s most complex neurologic diseases.
By combining Brigham and Women’s Hospital’s unique assets with the world’s most advanced resources and minds, the center is pursuing life-giving breakthroughs that are providing enduring hope and empowerment to individuals confronting these devastating neurologic diseases and changing outcomes for future generations.
The Ann Romney Center for Neurologic Diseases is a catalyst that fuels collaboration among the global medical and scientific communities in pursuit of treatments and cures for neurologic diseases.
Dr. Roberta Brinton, M.D.
Roberta Diaz Brinton, PhD is Director of the Center for Innovation in Brain Science at the University of Arizona Health Sciences, where she is Professor of Pharmacology and Neurology in the College of Medicine. Brinton serves on Boards of the Alzheimer’s Drug Discovery Foundation and NIH Center for Scientific Review. Brinton is an innovative and creative neuroscientist whose early insights led to the leadership position she holds today in the field of Alzheimer’s, the aging female brain and regenerative therapeutics to prevent, delay and treat the disease.